Blood typing has become a routine test item of clinical blood transfusion department and clinical laboratory, which includes ABO blood group, Rh blood group, and cross-matching of blood test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 27, 2025.

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2025.

Danaher reported a 5 percent year-over-year increase in third quarter revenues on Tuesday that was partially due to higher-than-anticipated revenues from Cepheid's respiratory testing business.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site.

At the annual IDWeek meeting (https://idweek.org/), Bruker announced the U.S. Food and Drug Administration (FDA) clearance of Claim 7 and Claim 8 for its MALDI Biotyper® CA System, marking a significant advancement in clinical microbial identification capabilities. The clearance includes the MBT Compass HT CA software and MBT FAST™ Shuttle US IVD (Claim 7), as well as a major expansion of the FDA-cleared reference library (Claim 8), now encompassing 549 clinically validated microbial species across gram-positive and gram-negative bacteria, anaerobes and yeasts.

With the development of the blood coagulation industry, more and more IVD companies have joined it and actively expanded the related services.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

MVZ HPH Institute for Pathology and Hematopathology GmbH, today announced the availability of HPH MRD, a new tumor-informed circulating-tumor DNA (ctDNA) blood test for detecting minimal residual disease (MRD) in patients diagnosed with solid tumor cancers. The HPH MRD test is an in-house test manufactured by HPH that makes use of Haystack MRD technology and is available through a license from Haystack Oncology, a subsidiary of Quest Diagnostics® (NYSE: DGX), which developed and provides the Haystack MRD in-house developed test in the United States. The technology was purpose-built to detect ultralow levels of ctDNA with exceptional sensitivity and specificity, enabling the reliable identification of residual or recurrent disease.

Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read technology, evaluating its performance on regions of the genome that traditional short-read technologies historically have not resolved. GeneDx's early results illustrate the ability of constellation to rapidly identify hard-to-detect variants implicated in rare disease. GeneDx's Director of Laboratory Innovation Joe Devaney will present on the company's early experiences with the constellation technology today at the American Society for Human Genetics (ASHG) Annual Meeting in Boston.

In preliminary results reported on Wednesday after the close of the market, Becton Dickinson said its revenues in the fiscal fourth quarter of 2025 increased 8 percent year over year. The firm also announced the upcoming departure of its CFO and disclosed a transition plan for the position.